Allie Nawrat

You can get in touch with Allie on Alexandra.Nawrat@verdict.co.uk

All articles by Allie Nawrat

  1. BioLive pinpoints possible collaborative areas in pharma

    UBM-supported whitepaper from BioLive and CPhi Pharma has identified three main areas where the expertise of the small molecule field…
    Read More…

    29 Jun
  2. Aquinox halts development of its drug for bladder pain syndrome

    Canada-based Aquinox Pharmaceuticals has announced that it will stop developing the drug rosiptor (AQX-1125) following the failure of its LEADERSHIP…
    Read More…

    28 Jun
  3. Celgene and Skyhawk initiate five-year collaboration for neurological diseases

    Celgene has entered into a five-year global strategic collaboration with drug discovery and development company Skyhawk Therapeutics with an upfront…
    Read More…

    27 Jun
  4. Kaleido ends oversubscribed funding round at $101m

    Microbiome startup Kaleido Biosciences has closed its oversubscribed Series C financing round at $101m. Investment came from Fidelity Management, Invus,…
    Read More…

    26 Jun
  5. Study shows almost half of UK women experience ‘serious trouble’ with contraception

    A study by educational women’s health website Femedic records that 47% of women in the UK have had ‘serious trouble’…
    Read More…

    20 Jun
  6. Sandoz becomes first Canadian pharmaceutical company to enter medical cannabis field

    Subsidiary of Sandoz International, Sandoz Canada, has finalised its alliance with Health Canada-licensed medical cannabis producer Tilray to improve Canadians’…
    Read More…

    20 Jun
  7. Janssen presents data for its esketamine nasal spray for depression

    Johnson & Johnson subsidiary Janssen has presented its Phase 3 data for its esketamine nasal spray for treatment-resistant depression for…
    Read More…

    19 Jun
  8. Talking generics in the UK with Mylan’s Jean-Yves Brault

    In 2009, the US Food and Drug Administration (FDA) accepted Mylan’s new drug application (NDA) for Brabio, the first generic…
    Read More…

    19 Jun
  9. FDA awards PRV for not-for-profit’s river blindness treatment

    The US Food and Drugs Administration (FDA) has approved not-for-profit Medicines Development for Global Health’s (MDGH) moxidectin 8mg oral treatment…
    Read More…

    19 Jun
  10. Johnson & Johnson sells LifeScan to Platinum Equity

    Global pharmaceutical company Johnson & Johnson has accepted investment firm Plantinum Equity’s offer to acquire LifeScan, its blood glucose monitoring…
    Read More…

    15 Jun
Close
Close
Close

Go Top